Below are the most recent publications written about "Ribavirin" by people in Profiles.
-
Shah AP, Cameron A, Singh P, Frank AM, Fenkel JM. Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens. Transpl Infect Dis. 2017 Apr; 19(2).
-
Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, Reddy KR, Lawitz E, Flamm SL, Schiano T, Teperman L, Fontana R, Schiff E, Fried M, Doehle B, An D, McNally J, Osinusi A, Brainard DM, McHutchison JG, Brown RS, Charlton M. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015 Dec 31; 373(27):2618-28.
-
Harrington PR, Fleischer R, Connelly SM, Lewis LL, Murray J. Reply to Merli et al. Clin Infect Dis. 2016 Feb 15; 62(4):528-9.
-
Harrington PR, Fleischer R, Connelly SM, Lewis LL, Murray J. Ribavirin Reduces Absolute Lymphocyte Counts in Hepatitis C Virus-Infected Patients Treated With Interferon-Free, Direct-Acting Antiviral Regimens. Clin Infect Dis. 2015 Sep 15; 61(6):974-7.
-
Knorr JP, Chewaproug D, Neeli S, Torres E, Zaki R. Severe Interferon/Ribavirin-Induced Hyperuricemia and Urate Nephropathy Requiring Rasburicase and Hemodialysis in a Liver Transplant Recipient. Exp Clin Transplant. 2015 Dec; 13(6):596-9.
-
Sterling RK, Kuo A, Rustgi VK, Sulkowski MS, Stewart TG, Fenkel JM, El-Genaidi H, Mah'moud MA, Abraham GM, Stewart PW, Akushevich L, Nelson DR, Fried MW, Di Bisceglie AM. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Aliment Pharmacol Ther. 2015 Apr; 41(7):671-85.
-
Curry MP, Forns X, Chung RT, Terrault NA, Brown R, Fenkel JM, Gordon F, O'Leary J, Kuo A, Schiano T, Everson G, Schiff E, Befeler A, Gane E, Saab S, McHutchison JG, Subramanian GM, Symonds WT, Denning J, McNair L, Arterburn S, Svarovskaia E, Moonka D, Afdhal N. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology. 2015 Jan; 148(1):100-107.e1.
-
Dvory-Sobol H, Voitenleitner C, Mabery E, Skurnac T, Lawitz EJ, McHutchison J, Svarovskaia ES, Delaney W, Miller MD, Mo H. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother. 2014 Nov; 58(11):6599-606.
-
Pfeffer LM, Li K, Fleckenstein JF, Marion TN, Diament J, Yang CH, Pfeffer SR, Fan M, Handorf E, Handorf CR. An interferon response gene signature is associated with the therapeutic response of hepatitis C patients. PLoS One. 2014; 9(8):e104202.
-
Yang H, Robinson M, Corsa AC, Peng B, Cheng G, Tian Y, Wang Y, Pakdaman R, Shen M, Qi X, Mo H, Tay C, Krawczyk S, Sheng XC, Kim CU, Yang C, Delaney WE. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Antimicrob Agents Chemother. 2014; 58(2):647-53.